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ABSTRACT 
Dutasteride, used for treating benign prostate hyperplasia (BPH), promotes hair growth.  
To enhance delivery to the hair follicles and reduce systemic effects, in this study 
dutasteride has been formulated for topical application, in a nanostructured lipid carrier 
(NLC) coated with chitosan oligomer-stearic acid (CSO-SA). CSO-SA has been 
successfully synthesized, as confirmed using 1H NMR and FTIR. Formulation of 
dutasteride-loaded nanostructured lipid carriers (DST-NLCs) was optimised using a 23 
full factorial design. This formulation was coated with different concentrations of stearic 
acid-chitosan solution.  Coating DST-NLCs with 5% SA-CSO increased mean size from 
187.6 ± 7.0 nm to 220.1 ± 11.9 nm, and modified surface charge, with zeta potentials 
being -18.3 ± 0.9 mV and +25.8 ± 1.1 mV for uncoated and coated DST-NLCs 
respectively. Transmission electron microscopy showed all formulations comprised 
approximately spherical particles. DST-NLCs, coated and uncoated with CSO-SA, 
exhibited particle size stability over 60 days, when stored at 4-8°C. However, NLCs 
coated with CSO (without conjugation) showed aggregation when stored at 4-8°C after 
30 days. The measured particle size for all formulations stored at 25°C suggested 
aggregation, which was greatest for DST-NLCs coated with 10% CSO-SA and 5% 
CSO. All nanoparticle formulations exhibited rapid release in an in vitro release study, 
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with uncoated NLCs exhibiting the fastest release rate. Using a Franz diffusion cell, no 
dutasteride permeated through pig ear skin after 48 h, such that it was not detected in 
the receptor chamber for all samples. The amount of dutasteride in the skin was 
significantly different (p<0.05) between DST-NLCs (6.09 ± 1.09 µg/cm2) without 
coating and coated with 5% CSO-SA (2.82 ± 0.40 µg/cm2), 10% CSO-SA (2.70 ± 0.35 
µg/cm2) and CSO (2.11 ± 0.64 µg/cm2). There was a significant difference (p<0.05) in 
the cytotoxicity (IC50) between dutasteride alone and in the nanoparticles. DST-NLCs 
coated and uncoated with CSO-SA increased the maximum non-toxic concentration by 
20-fold compared to dutasteride alone. These studies indicate that a stearic acid-chitosan 
conjugate was successfully prepared, and modified the surface charge of DST-NLCs 
from negative to positive. These stable, less cytotoxic, positively-charged dutasteride-
loaded nanostructured lipid carriers, with stearic acid-chitosan oligomer conjugate, are 
appropriate for topical delivery and have potential for promotion of hair growth. 
Keywords: alopecia, chitosan conjugation, dutasteride, nanostructured lipid carriers, 
topical delivery 
 
1.0 INTRODUCTION 
Androgenic alopecia (AGA, male-pattern baldness) affects almost 50% of men 
during their lives [1]. Androgen is one of the prerequisites for male-pattern baldness [2]. 
Normally, patients with androgenic alopecia have higher levels of dihydrotestosterone 
(DHT) and 5-α reductase enzyme activity on their balding scalp area than those with a 
non-balding scalp area [3]. In hair-loss patients, testosterone is converted to DHT which 
results in miniaturization of the hair follicle and hair shedding [4]. There are two types 
of enzymes that contribute to androgenic alopecia: type I 5α-reductase enzyme is present 
in the skin, including scalp, and type II is in the hair follicles and prostate [5]. 
Dutasteride (a type I and type II 5α-reductase inhibitor) is approved by the US Food and 
Drug Administration (FDA) for treating benign prostate hyperplasia (BPH), and has 
been studied for hair growth efficacy, with an oral dose of 0.5 mg daily [6].   Dutasteride 
taken orally will reduce DHT levels throughout the body. In order to reduce the systemic 
effects of lowered DHT levels, such as diminished sexual desire, increased depression 
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and ejaculation disorder [7,8], topical administration of dutasteride for treating AGA 
would be an appropriate drug-delivery strategy. Little research has been conducted 
using dutasteride for topical application. Ansari et al. [9] prepared nanoemulsions using 
different ratios of oleic acid and eucalyptus oil for delivery to the skin, in the size range 
of approximately 20-210 nm; no information on surface charge, entrapment efficiency 
or drug loading was provided. Madheswaran et al. [10] used monoolein to produce 
liquid crystalline nanoparticles of finasteride and dutasteride, surface-modified with 
chitosan (low molecular weight) to give a positive charge.  The mean particle size was 
239-259 nm, with zeta potential +19.8 to +48.5 mV. The surface-modified nanoparticles 
enhanced transdermal delivery of the 5-α reductase inhibitors, increasing permeation of 
finasteride and dutasteride. No stability studies were undertaken. Unlike most previous 
studies of dutasteride employing oral administration, this work aims to achieve local 
delivery of dutasteride, by formulation in a nanostructured lipid carrier (NLC) system 
for topical delivery to the skin/hair follicles. Previous studies have determined the 
transfollicular delivery of materials, including drugs using nanoparticles. Lademann et 
al. [11] found that dye-containing nanoparticles with a mean size of 320 nm penetrated 
deeper into the hair follicles, when massage was applied, than the dye similarly applied 
in non-nanoparticulate form. Blume-Peytavi et al., [12] compared the transfollicular and 
percutaneous delivery of a minoxidil foam. Minoxidil was detected in the blood faster 
when the hair follicle orifices were opened compared to the blocked hair follicle orifices, 
demonstrating more rapid drug delivery and transport via the follicular route. Patzelt et 
al., [13] reported that the penetration depth of particles into the hair follicles was 
dependent on their size; medium sized particles (643 and 646 nm) penetrated deepest 
into porcine hair follicles, whereas smaller (122 nm, 230 nm, 300 nm and 470 nm) and 
larger particles (860 nm, 920 nm and 100 nm), penetrated the follicle, but to shorter 
depths.  
Nanostructured lipid carriers (NLCs) were introduced by Muller et al., [14] subsequent 
to solid lipid nanoparticles (SLNs), to overcome some of the limitations associated with 
SLNs. NLCs can increase loading capacity, physical and chemical long-term stability 
and prolong release of incorporated molecules. They are also suitable for topical 
formulations [15]. Different types of solid lipid can be used in the production of SLNs 
and NLCs. The term of solid lipid includes fatty acids (e.g. myristic, stearic and palmitic 
acid), triglyceride (e.g. tripalmitin and tristearin), diglyceride (e.g. glyceryl behenate), 
    
4 
 
monoglyceride (e.g. glyceryl monostearate), steroids (e.g. cholesterol) and waxes (e.g. 
cetyl palmitate and beeswax). Different types of solid lipid have different degrees of 
crystallization that may impact drug entrapment and loading, size and charge, and also 
efficacy. The lipid particle matrix is solid at both ambient and body temperatures [16]. 
In this study, stearic acid has been chosen as a solid lipid due to its potential for 
promoting hair growth [17]. Previous research [18] has demonstrated that free fatty 
acids (α-linolenic, linoleic, palmitic, elaidic, oleic and stearic acid) are potent 5α-
reductase inhibitors and promote hair regrowth. Inclusion of stearic acid in the 
formulation, might have an additional effect with dutasteride for the promotion of hair 
growth. Due to the properties of dutasteride, which is poorly water soluble (0.038 
ng/mL; Log P=5.09) [19], NLCs would seem useful as a potential carrier. NLCs 
composed of biocompatible and biodegradable lipids have low toxicity and cytotoxicity, 
are suitable for topical application and have an occlusive effect on the skin, increasing 
skin hydration [20]. Mittal et al. [21] reported that NLCs with a size of approximately 
300 nm were found in the transfollicular region of the skin. Hamishehkar et al. [22] 
found higher skin deposition of flutamide-loaded SLNs (volume mean diameter 
approximately 200 nm) compared to flutamide hydroalcoholic. This higher 
accumulation of flutamide-SLNs in the hair follicles suggested a greater growth of new 
hair follicles based on the histological assessment  
Chitosan, a naturally occurring polysaccharide, contains free amino groups, is 
cationic in neutral or basic pH conditions, and is commonly used for drug delivery 
applications, particularly where a positive charge is advantageous. Hair is negatively 
charged [23]; consequently, introducing a positive charge to nanoparticles may enhance 
targeting. It is also reported that due to the bioadhesive properties of chitosan, it may 
increase retention of the drug/carrier in the targeted area [24]. Taking this into account, 
DST-NLCs coated with a positively-charged, chitosan-based polymer have been 
investigated here for topical/transfollicular delivery. 
 
In the present study, stearic acid was selected for use as a lipophilic ingredient 
and synthesized with chitosan to enhance the lipophilicity of the aqueous-soluble 
chitosan. The carboxylic group of stearic acid was reacted with the amine group from 
chitosan with addition of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC.HCl), creating the hydrophobic drug-delivery moiety.  
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Therefore, it is suggested that when dutasteride is incorporated in the 
nanostructured lipid carrier (NLC), the drug will be entrapped in the hydrophobic region 
where surfactants are added to stabilize it.  A solution of stearic acid-chitosan (CSO-
SA) having a positive charge will coat the nanoparticles.  
 
The aim of this study is then to design and formulate a stable and less cytotoxic 
formulation of DST-NLCs coated with CSO-SA for the promotion of hair growth. This 
study anticipates that surface modification of DST-NLCs with CSO-SA would produce 
a slow release of the drugs in the skin/hair follicles with potential to reduce systemic 
effects.  
 
 
2.0 MATERIALS AND METHODS 
2.1 Materials 
Stearic acid was purchased from Tokyo Chemical Industry (UK). Chitosan oligomer 
(CSO), Mwt <3000Da and dutasteride (purity >98.0%) were obtained from Carbosynth 
(UK). Ethanol (96% v/v analytical grade), 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC.HCl), ninhydrin, Sephadex G-50 and acetic acid-d4 
(99.9 atom %D) were obtained from Sigma-Aldrich (UK). Deuterium oxide (99.9 atom 
%D) was purchased from Cambridge Isotope Lab. Inc. (USA), Phosal® 53 MCT and 
Lutrol® micro 68 were supplied by Lipoid GmbH (Germany) and BASF Group 
(Ludwigshafen, Germany), respectively. Acetone, water (HPLC grade) and acetic acid 
glacial (analytical reagent) were purchased from Fisher Scientific (United Kingdom). 
Deionized water was prepared in-house (PURELAB, ELGA, UK). 
2.2 Synthesis of stearic acid-chitosan (CSO-SA) 
Chitosan oligomer (CSO) was conjugated by the reaction of the carboxyl groups of 
stearic acid in the presence of EDC.HCl with the free amino groups of chitosan oligomer 
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(Fig.1), using an established method with minor modifications [25,26]. CSO (1 g) was 
dissolved in 120 mL of deionized water with magnetic stirring for 2 h at 80°C. 
Meanwhile, 0.5 g stearic acid (SA) was dissolved in ethanol (80 mL) and heated at 60°C, 
with stirring. SA solutions were activated by EDC.HCl (1:5 molar ratio) and stirred for 
2 h at 60°C. The solutions of SA were then added using a syringe with needle (BD Micro 
Lance™ 3, Spain) into the CSO solution with continuous stirring for 6 h.  
 
The product was evaporated under vacuum (Buchi Rotary evaporator, Buchi, 
Switzerland) at 70°C to reduce the volume. Unreacted EDC.HCl and SA were removed 
by dialysis (Mwt cut-off 1000 Da, Spectrum Laboratories, USA) for 2 days, then the 
product precipitated using 300 mL of acetone and filtered using filter paper (Fisherbrand 
QL100, Fisher Scientific, UK). This precipitation/filtration step was repeated three 
times. Samples were stored in a desiccator for further analysis. 
2.2.1 Characterization of chitosan oligomer-stearic acid using Fourier 
Transform Infrared Spectroscopy (FTIR) 
Samples of CSO-SA, CSO and SA were analysed using FTIR to confirm the 
presence of the SA group in the CSO chain. Samples were analysed with 4 scans from 
660 to 4000 cm−1 using PerkinElmer Spectrum100 FTIR (PerkinElmer, UK). The 
spectrum of CSO-SA was then compared to those of pure CSO and SA.  
2.2.2 Characterization of chitosan oligomer-stearic acid using 1H NMR  
In order to confirm the presence of the fatty acid chain in the chitosan conjugate, 
samples were characterised using nuclear magnetic resonance spectroscopy (NMR).  5 
mg of CSO, CSO-SA and SA was dissolved in 1 mL of deuterium oxide (D2O) with the 
addition of one drop of acetic acid-d4 in order to dissolve the product. The 
1H NMR 
spectra were obtained using a NMR Bruker Avance 500 spectrometer (Bruker 
Instruments, USA). 
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2.2.3 Determination of amine group substitution using ninhydrin assay 
The amount of chitosan conjugated with stearic acid was determined using 
ninhydrin as a reagent to react with the primary and secondary amino groups in the 
conjugated product [27]. The percent of free amino groups present in the CSO-SA 
conjugate was determined using the ninhydrin assay, by assuming the D-glucosamine 
slope has 100% amine groups, and the CSO and CSO-SA were then identified by 
comparing each slope. Serial dilutions of D-glucosamine (stock solution: 500 µg/mL), 
CSO and CSO-SA (stock solution: 2000 µg/mL) were prepared in 0.2% acetic acid 
solution. The working solutions for CSO and CSO-SA were 100, 60, 40 and 20 µg/mL 
and for D-glucosamine 25, 20, 15, 10, 5 µg/mL. To prepare the ninhydrin solution, 0.35 
g of ninhydrin was dissolved in 100 mL of ethanol.   
To start the reaction, 0.5 mL of CSO or CSO-SA solutions, 0.5 mL of 4M acetate 
buffer (pH 5.5) and 2 mL of ninhydrin solution were combined and heated at 90°C in a 
water bath with stirring for 15 min, then cooled to room temperature. The solution was 
then made up to 10 mL with ethanol. The absorbance was measured at 570 nm using 
Agilent Cary 100 UV-Vis Spectroscopy (Agilent Technologies UK Ltd., Berkshire, 
UK). The amounts of free amine groups in CSO and CSO-SA samples were assigned 
by comparing the slopes using linear regression from D-glucosamine where the 
absorbance (y) for each sample was plotted as a function of concentration (x). 
2.3 Preparation of dutasteride-loaded nanostructured lipid carriers (DST-
NLCs) 
DST-NLCs were prepared by the melt-dispersion ultrasonication method [28–30]. 
Dutasteride (5 mg), stearic acid and Phosal® 53 MCT were weighed into a glass vial. 
Lutrol® micro 68 was added into another glass vial with water (10 mL). Both glass vials 
were heated separately at 80-90°C in a water bath. When the drug completely dissolved 
in the liquid lipid (by magnetic stirring), the aqueous solution was added into the oil-
phase solution. The mixture was homogenized using an IKA Ultra Turrax T25 (IKA 
Werke, Germany) at 19,000 rpm for 10 min. The hot solution was further processed 
using a probe-type sonicator (MSE Soniprep 150, MSE, UK) at 18W, for 5 min. 2 mL 
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of hot dispersion was syringed (needle: 25 gauge, 5/8th inch) into 10 mL of cold water 
(4-8°C) and stirred for 10 min to obtain nanoparticles. The formulation was stored at 4-
8°C before being characterised. The weight of dutasteride was 5 mg, and 10 mL of water 
was used for all formulations.  
2.3.1 Experimental design of preparation of DST-NLCs using 23 full factorial 
design 
The amount of solid lipid and surfactant used to prepare DST-NLCs was varied to obtain 
the smallest mean particle size, narrowest size distribution, and highest entrapment 
efficiency and drug loading. This was achieved with a 23 full factorial design, Design 
Expert 6.0.8 Software (Stat-Ease, USA). The three factors evaluated were: the content 
of stearic acid (A), Lutrol® micro 68 (B) and Phosal® 53 MCT (C) (Table 1). 
A factorial design was used to obtain maximum information, such as the 
interaction between the factors, whilst minimising the number of experiments [31]. The 
design required, in total, 8 preparations. The experiments were repeated three times to 
calculate the experimental error.  
2.3.2 Preparation of DST-NLCs coated with chitosan oligomer (CSO) and 
stearic acid-chitosan (CSO-SA) 
The optimised DST-NLC preparation was chosen based on statistical analysis. 
The formulation was scaled up from 100 mg to 300 mg of stearic acid to allow use of 
the desired concentration of dutasteride (approximately 0.3 mg/mL). Quantities of other 
materials (dutasteride, Phosal® 53 MCT and Lutrol® micro 68) were up-scaled using 
the same ratio, with water kept constant at 10 mL. The amount of dutasteride was 
optimised between 15 and 20 mg. CSO-SA (5 or 10 % of solid lipid content) and CSO 
(5% of solid lipid content) were dissolved in acidified water (0.2% acetic acid in 
deionized water). 250 µL of the solution was added, using a syringe (needle: 25 gauge, 
5/8th inch), into 5 mL of DST-NLCs with constant stirring for 10 min.      
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2.4 Characterization of DST-NLCs, uncoated and coated with CSO-SA or CSO 
2.4.1 Measurement of particle size distribution, zeta potential and 
determination of nanoparticle morphology 
The size distribution and zeta potential of nanoparticles were obtained as ZAve 
hydrodynamic diameter, polydispersity index (PDI) and zeta potential (ξ) using a 
Zetasizer Nano ZS (Malvern Instruments, UK) after 1 day, at 25°C. Formulations were 
prepared with deionized water (pH 5.6) and used without further dilution. 1 mL of the 
sample was pipetted directly into the zeta potential DTS1070 folded capillary cell 
(Malvern, UK) without dilution. Measurements were performed 3 times, and mean 
values were taken. Zeta potential was calculated from electrophoretic mobility using the 
Helmholtz-Smoluchowski equation by the Malvern data analysis software..  
The morphology of the nanoparticles was determined using transmission electron 
microscopy (TEM; Philips/FEI CM120 Bio Twin, FEI Netherlands). Samples were 
placed on copper grids for viewing and excess droplets were wicked away with filter 
paper [32]. After 2 min, a drop of 1% phosphotungstic acid was placed onto the copper 
grid for negative staining. The grid was dried at room temperature and observed using 
TEM. 
2.4.2 Entrapment efficiency and drug loading  
Entrapment efficiency and drug loading were calculated as described previously 
[33], with modification.  Entrapment efficiency and drug loading were determined using 
Sephadex® gel G-50 as a mini column. 5 mL of gel was packed in a 5 mL syringe, 
placed in a centrifuge tube (size of 50 mL) and centrifuged at 1000 rpm (angle rotor 
19776-H, at 104 x g) for 10 s in a refrigerated centrifuge (Sigma Laborzentrifugen, 
Germany) at 20°C to remove excess water. Then, 0.5 mL DST-NLC preparation was 
pipetted in the middle of the column and separated by column chromatography at 1000 
rpm for 5 min. The column was washed with 0.5 mL deionized water at 1000 rpm for a 
further 5 min. The collected sample, dutasteride entrapped in NLCs, was diluted with 
ethanol in a 10 mL volumetric flask and sonicated for 10 min to dissolve the particles 
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before filtration using a 0.22 µm pore size syringe filter (Merck Millipore, Ireland). 
Unentrapped dutasteride was retained in the Sephadex G-50 gel. The ethanolic solution 
was assayed using a validated HPLC method to determine the total and entrapped 
dutasteride in the DST-NLCs.  
High performance liquid chromatography (HPLC) with UV/Vis detector (Agilent 
1100 Series, USA) at wavelength 241 nm was used to quantify dutasteride in 
preparations. The analytical column, Synergi™ 4 µm Polar-RP 80 Å, 250 x 4.6 mm was 
selected as the stationary phase. Separation was carried out using a mobile phase 70:30 
(by volume) of acetonitrile and 0.1% trifluroacetic acid (TFA) in HPLC grade water. 
The injection volume used was 30 µL at 1 mL/min flowrate. 
Encapsulation efficiency was calculated from the amount of entrapped (𝑛1) and 
total dutasteride in the preparation (𝑛2) (Equation 1). Dutasteride loading was calculated 
using Equation 2. 
Entrapment efficiency (%) = 
𝒏𝟏
𝒏𝟐
 × 100            Equation 1 
where; 
𝑛1 = concentration of entrapped dutasteride in DST-NLCs  
 𝑛2= total concentration of dutasteride in DST-NLCs 
 
Drug loading (%) = 
𝑪𝟏
𝑪𝟎
 × 100               Equation 2 
 
where; 
𝐶1 = total weight of entrapped dutasteride in DST-NLCs  
 𝐶0= total weight of solid lipid, surfactant and dutasteride in DST-NLCs 
2.4.3 Stability study 
The stability of DST-NLCs was investigated to explore potential changes in the size 
distribution and surface charge with time. Each formulation was stored in a refrigerator 
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at 4-8°C and at 25°C (incubator). Particle size distribution and zeta potential were 
compared at day 1, 30 and 60. 
2.5 In vitro drug release 
In vitro release was studied using a Franz diffusion cell (PermeGear, USA). A 0.45 µm 
HA nitrocellulose membrane (MF™ Membrane Filters, Merck Millipore, Ireland) was 
mounted in the Franz diffusion cell (surface area = 0.64 cm2) maintained at 37°C and 
stirred using a magnetic stirrer (600 rpm). Due to the limited solubility of dutasteride in 
phosphate-buffered saline (PBS), 2% sodium dodecyl sulphate (SDS) was added. DST-
NLCs, with or without chitosan (250 µL), were pipetted in the donor chamber and 
sampling (200 µL) was done at 0, 0.25, 0.5, 1, 2, 3, 6, 8, 12, 24, 30 and 36 h from the 
receptor chamber, replaced with 200 µL fresh buffer. Samples were injected into the 
HPLC to determine drug released.  
2.6 In vitro permeation 
An in vitro permeation study was conducted to quantify the amount of drug present in 
the skin and potential systemic exposure. In order to mimic topical application of the 
formulation, in vitro permeation was performed using a vertical Franz diffusion cell 
(PermeGear, USA). Pig ears were obtained from a local slaughterhouse (Farnborough, 
UK) from a freshly slaughtered pig (used for food consumption). The ears were washed 
with deionized water and hairs were trimmed carefully with scissors. The pig ear skin 
was excised using a scalpel and forceps and the subcutaneous tissue was removed. The 
average thickness of the skin was ~0.5 mm. The skin was cut and frozen (-20°C) for 
future use.   
 
The diffusion surface area of the Franz cell was 0.64 cm2. The receptor chamber 
was filled with 5 mL of PBS (pH 7.4) with 2% SDS and 0.02% sodium azide and 
maintained at 37°C whilst being stirred using a magnetic stirrer. The skin was mounted 
between the donor and receptor chambers and allowed to equilibrate for 1 h. 250 µL of 
DST-NLCs formulation, with or without chitosan, was pipetted in the donor chamber. 
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200 µL samples were withdrawn at 0, 0.25, 0.5, 1, 2, 3, 6, 8, 12, 24, 30, 36 and 48 h, 
and 200 µL fresh buffer added to the receptor chamber. Nanoparticle formulations were 
compared to ethanolic solutions of dutasteride (0.29 mg/mL in 70% ethanol). After 48 
h, the stratum corneum was removed using a tape stripping method. The 
epidermis/dermis was chopped into small pieces using a scalpel and stirred for 24 h with 
ethanol and sonicated for 1 h. The solution was filtered and injected into the HPLC for 
quantification of the drug which permeated in the skin.  
2.7 In vitro cytotoxicity study on hair follicle dermal papilla cells 
In order to determine the maximum non-toxic concentration (EC90) of unencapsulated 
and encapsulated dutasteride in nanoparticles, MTT assays on normal hair follicle 
dermal papilla cells were undertaken. Human hair follicle dermal papilla cells 
(HFDPCs) (Promo- Cell, Germany) were grown in HFDPCs growth medium (Promo-
Cell, Germany) containing 100 IU/ml penicillin/streptomycin (Gibco-BRL, USA) and 
2.5 µg/ml of amphotericin B (Sigma-Aldrich, UK) in a humidified 95% atmosphere 
with 5% CO2 at 37°C. Cultured HFDPCs from passage 4 were seeded (3.75 x 10
4 per 
mL) into 96-well plate (Nunc, Wiesbaden, Germany) and grown to a confluence of 60–
70% for 24 h. The MTT assay was conducted for 5 days with dutasteride alone 
(dutasteride alone was dissolved in DMSO at 100 mM and serial dilutions were prepared 
from 100 to 1.6 µM), dutasteride in the nanoparticles coated or uncoated with CSO-SA 
(12.5 - 100 µM) and empty NLCs coated and uncoated with CSO-SA (at the same 
concentration as DST-NLCs and DST-NLCs CSO-SA). MTT (5 mg/mL) was added to 
each well, and cells were incubated for 4 h at 37°C. The supernatant was then removed, 
and 100 µL of dimethylsulfoxide was added to dissolve formazan products. Absorbance 
was determined spectrophotometrically at 570 nm using microplate reader 
(SpectraMax®M2e, Molecular Devices, USA). Results were expressed as percentages 
of untreated controls in four cultures. Reported values represent means ± SEM. 
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2.8 Statistical analysis 
All data were analysed either using a t-test or one-way ANOVA and Tukey’s post-hoc 
test, using IBM SPSS Statistic 22, except data from the experimental design for the 
model (formulations) which were analysed using Design Expert 6.0.8 Software (Stat-
Ease, USA). A p-value of less than 0.05 was considered significant.  
 
3.0 RESULTS AND DISCUSSION 
3.1 Synthesis and characterization of CSO-SA 
3.1.1 1H NMR and FTIR  
Formation of the CSO-SA conjugate was determined using FTIR and 1H NMR. The IR 
spectrum of CSO-SA showed two peaks at around 1636 and 1584 cm-1 corresponding 
to the N-stearoyl (amide bond) (Fig. 2a). The increase of the C-H absorption around 
~2855 cm-1 indicated the presence of the stearoyl chain. The chemical shifts shown at 
1.0 - 1.1 ppm in the NMR spectrum represent protons from CH3 of stearic acid whereas 
the peaks at 1.13 - 1.15 ppm correspond to protons of CH2 in the acyl chain (Fig. 2b). 
This finding agrees with previous studies [34,35]. The remaining peaks are due to 
hydrogen from the chitosan oligomer, indicating that stearic acid was conjugated to the 
chitosan oligomer. 
3.1.2 Degree of substitution determined by ninhydrin assay 
Based on the ninhydrin assay, the slopes for D-glucosamine and chitosan oligomer 
(CSO) and CSO-SA were 0.0676, 0.0126 and 0.0093, respectively. The number of 
amine groups on the chitosan oligomer was found to decrease due to the substitution of 
stearic acid. By comparing the slope from D-glucosamine and CSO; the percent degree 
of substitution (%DS) of CSO-SA was calculated to be 6.0%.  
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3.2 Preparation, optimization and characterization of DST-NLCs coated and 
uncoated with CSO-SA/CSO 
3.2.1 Factorial design results on particle size distribution of DST-NLCs 
DST-NLCs were prepared according to a design of experiments. The main 
independent factors that might influence the particle size distribution were the contents 
of stearic acid, Lutrol ® F68 and Phosal® 53 MCT. All of the formulations gave mean 
size larger than 100 nm (Fig. 3).  
 
Experimental design was employed to find the best model that relates the ratio 
of solid lipid and surfactant to mean particle size and PDI (a measure of the width of the 
size distribution). At day 1, there was no significance model term for the hydrodynamic 
diameter results (p>0.05), suggesting high stability of the particles for the quantities of 
materials used. To obtain optimised, stable particles, the NLCs were stored at 4-8°C for 
14 days (Fig. 3), revealing a significant difference in the model term for the 
hydrodynamic diameter at day 14 (p<0.05). 
 
From the modelling at day 14, the ‘Predicted R-Squared’ (0.8058) was in 
reasonable agreement with the ‘Adjustment R-Squared’ (0.9150). Table 2 shows the 
results of ANOVA on hydrodynamic diameter at day 14, indicating that some 
formulations were unstable, with increased hydrodynamic diameters after two weeks. 
The mathematical modelling of DST-NLCs on hydrodynamic diameter followed 
Equation 3 (coded value at day 14):   
Hydrodynamic diameter (nm) = 344.60 – 73.35*A  
      + 31.10*B – 78.90*A*B       Equation 3 
 
Where; 
A – Stearic acid  
B – Lutrol® micro 68  
C – Phosal® 53 MCT 
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Fig. 4a shows the interaction between stearic acid (A) and Lutrol® micro 68 (B) 
on hydrodynamic diameter. 100 mg stearic acid, 50 mg Lutrol® micro 68 and 25 or 50 
mg Phosal® 53 MCT produced the smallest particles (S4 and S8), having a mean 
diameter of 223.5 nm. Increasing surfactant content stabilized the nanoparticles, with a 
reduction in mean size. Hydrophilic-Lipophilic Balance (HLB) is a major consideration 
in making stable emulsions. In this study, Lutrol ® F68 has a high HLB value (>24) and 
soy phosphatidycholine (53% in Phosal® 53 MCT) has a low HLB value (4). Using a 
mix of emulsifiers can stabilize the emulsion in terms of coalescence rate  [36]. 
Model A, C, AB and AC were significantly different (p<0.05) on PDI at day 14 
(Table 3). ‘Predicted R-Squared’ (0.9761) from the model was in reasonable agreement 
with the ‘Adjustment R-Squared’ (0.9948).      Equation 4 
shows the model for PDI at day 14 (in coded value).  
(PDI)  = 0.23 – 0.048*A + 4.750 x 10-3*B + 0.042*C  
   – 0.038*A*B – 0.015*A*C                  Equation 4 
 
where; 
A – Stearic acid  
B – Lutrol® micro 68 
C – Phosal® 53 MCT  
 
Figs. 4b and 4c show a 3D-surface graph of the interaction between stearic acid 
(A), Lutrol® micro F68 (B) and stearic acid with Phosal® 53 MCT (C). 100 mg stearic 
acid, 50 mg Lutrol® micro 68 and 25 mg Phosal® 53 MCT (Formulation S4), produced 
NLCs with a narrow particle size distribution (PDI=0.123). When the amount of 
surfactant was increased, PDI decreased with a mondispersed size distribution. It has 
been shown in the previous research that by increasing the surfactant, the particle size 
was decreased at certain concentration [36]. At low concentrations of surfactant, 
aggregation is accelerated where the fraction of particle surface area which is coated 
remains small. At higher surfactant concentration, all the agglomerated particles are 
coated and the particle size is reduced [36]. This allows ease of dispersion, reduced 
aggregation and hence a reduction in PDI.   
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3.2.2 Factorial design results for surface charge  
Fig. 5 shows all particles had negative charge due to the presence of the stearic acid. 
There was no significant difference (ANOVA, p>0.05) on the model for zeta potential 
at day 1 or day 14. Based on the results for hydrodynamic diameter and PDI, formulation 
S4 and S8 were chosen and further analysed using a t-test, which revealed no significant 
difference (p>0.05) for zeta potential between S4 and S8. 
3.2.3 Factorial design results for entrapment efficiency and drug loading 
The entrapment efficiency (%EE) for all formulations was greater than 60% (Table 4). 
Table 5 shows ANOVA results for entrapment efficiency. Based on the results (Fig. 6), 
model A and AB were significantly different (p<0.05). Based on the model, 100 mg 
stearic acid, 50 mg Lutrol® micro 68 and 25 or 50 mg Phosal® 53 MCT produced 
highest entrapment efficiency (95.1%). The content of stearic acid and the interaction 
between stearic acid and Lutrol® micro 68 significantly impacted EE% (p<0.05). 
However, there was no significant impact on drug loading (p>0.05), with the mean drug 
loading for all formulations being in the range 2 to 4.40%.  
The mathematical modelling of entrapment efficiency for DST-NLCs followed 
Equation 5 (coded value): 
EE% = 82.14 + 10.24*A – 2.61*B + 5.29*A*B                            Equation 5 
Where; 
A – stearic acid  
B – Lutrol® micro 68 
C – Phosal® 53 MCT 
3.2.4 Stability of DST-NLCs on storage 
Hydrodynamic diameter and particle size distribution were studied on day 1 and 
14 (Fig. 3). There were no significant differences (p>0.05) in the hydrodynamic 
diameter at day 1. At day 14, some formulations demonstrated an increase in mean size, 
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especially S3 and S7. This may be due to the amount of surfactant present being 
insufficient to stabilize the formulations. The results indicate that the ratio of contents 
in S4 (100 mg stearic acid, 50 mg Lutrol® micro 68 and 25 mg Phosal® 53 MCT) and 
S8 (100 mg stearic acid, 50 mg Lutrol® micro 68 and 50 mg Phosal® 53 MCT) gave 
the smallest hydrodynamic diameter and PDI at day 1 and day 14. There was no 
significant difference (p>0.05) between S4 and S8 at day 1, and 14 with respect to 
hydrodynamic diameter and PDI. Consequently, Formulation S4 was selected for the 
subsequent investigations.   
3.2.5 Effect of scale-up of the DST-NLCs preparation  
Formulation S4 was selected, as indicated above, and production quantities scaled up 
3x. Mean hydrodynamic diameter and PDI were not significantly altered (p>0.05; data 
not shown). Then, the amount of dutasteride was varied and 17.5 mg dutasteride was 
found to be the optimal content, giving highest entrapment efficiency (97.8 ± 0.68%). 
When drug content was increased to 20 mg, entrapment efficiency decreased to 90.1 ± 
1.07%, indicating the limitation of the amount of drug that can be loaded in this carrier 
system, as reported previously [37]. Furthermore, there was no significant difference 
(p>0.05) in drug loading (3.49 ± 0.10%). 
3.2.6 Particle size distribution of DST-NLCs uncoated and coated with CSO-SA 
and CSO 
The nanoparticles were coated with CSO and CSO-SA using a physical adsorption 
method. There was a significant increase in mean size following coating (p<0.05), from 
187.6 ± 7.0 nm to 220.1 ± 11.9 nm and 230.1 ± 8.2 nm when coated with 5 and 10% 
CSO-SA, respectively. Coating with 5% CSO, the size was 208.4 ±1.6 nm (p>0.05). 
There was not significant difference (p>0.05) in PDI for the preparations, with mean 
PDI <0.2, indicating all had narrow size distributions.  
Based on the TEM images, uncoated DST-NLCs and those coated with CSO/CSO-SA 
were spherical (Fig. 7) and in the size range approximately 200-250 nm. There was some 
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suggestion of aggregation for DST-NLCs coated with 10% CSO-SA (Fig. 7D), probably 
due to the higher concentration of CSO-SA. 
3.2.7 Zeta potential of DST-NLCs before and after coating 
The zeta potential of DST-NLCs changed from negative to positive on coating (p<0.05), 
with CSO-SA or CSO adsorbed to negatively-charged DST-NLCs, producing 
positively-charged nanoparticles. Zeta potential value was increased from +26.0 ± 1.1 
mV to +30.0 ± 1.2 mV for 5% to 10% of CSO-SA (p<0.05). The charge was higher for 
DST-NLCs coated with 5% CSO-SA than with 5% CSO (21.7 ± 2.1mV) (p<0.05). 
These findings indicated good interaction between DST-NLCs and CSO-SA, stabilizing 
the nanoparticles. This may result in part, from CSO-SA having some amphiphilic 
properties, as reported by Hu et al. [35] who produced stable doxorubicin-loaded 
polymeric micelles of a chitosan oligosaccharide-stearic acid conjugate. Moreover, the 
highly positively-charged CSO-SA will be electrostatically attracted to the negatively-
charged surface of DST-NLCs. Previous studies [24,38–41] have demonstrated the 
electrostatic interaction between positively-charged chitosan and negatively-charged 
nanoparticles. 
3.2.8 Stability of DST-NLCs uncoated, and coated with CSO-SA and CSO 
DST-NLCs coated with 10% CSO-SA and 5% CSO aggregated when stored at 25°C 
(Table 6). However, uncoated DST-NLCs and those coated with 5% CSO-SA and 10% 
CSO-SA were stable at 4-8°C over a period of 60 days. DST-NLCs coated with 5% 
CSO-SA and 10% CSO-SA, had unchanged mean particle size and PDI at day 1, 30 and 
60 (p<0.05). However, DST-NLCs coated with 5% CSO demonstrated physical 
instability, with aggregation even when stored at 4-8°C (day 30), possibly due to 
differences in the physical properties of the CSO compared to CSO-SA. 
When uncoated DST-NLCs and those coated with 5% CSO-SA were stored at 
25°C, the mean particle size increased by 2-fold compared to samples stored at 4-8°C. 
NLCs coated with 5% CSO, stored at 25° were aggregated at day 30. This might be due 
to the changes in polymer behaviour at different temperatures [42]. Increasing the 
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concentration of CSO-SA from 5% to 10% produced aggregation, possibly resulting 
from excess CSO-SA in the formulation, not associated with the NLC coating. The data 
indicate NLCs coated with chitosan without conjugation were relatively unstable. 
Having the hydrophobic chain (steroyl chain) in the chitosan-conjugate may enhance 
the stability of the nanoparticles, when the CSO-SA (at an appropriate concentration) 
was employed as a coating material.  
 
3.2.9 In vitro release from uncoated and coated DST-NLCs 
All nanoparticle preparations showed rapid release over the first 12 h (Fig. 8), with 
uncoated DST-NLCs exhibiting fastest release (p<0.05). There was no significant 
difference (p>0.05) between DST-NLCs coated with 5% and 10% CSO-SA, both 
having approximately 60% drug release at 36 h. 
DST-NLCs without coating showed 72% release at 24 h. DST-NLCs coated with CSO-
SA had a lower drug release due to the presence of the polymer in the outer regions of 
the particles. In contrast, DST-NLCs coated with 5% CSO (no conjugation) showed a 
slower release where 40.7 ± 5.1% of drug has been released at 36 h. Dutasteride in 70% 
ethanol (as control) showed only 32.6 ± 10.7% release at 36 h into the receptor media, 
probably due to the limited solubility of dutasteride in the receptor media. No 
precipitation was observed in the donor chamber after the experiment. The result was 
similar to that described previously whereby diphencyprone (slightly soluble in water) 
was released more slowly from ethanolic solution than from NLCs or a nanoemulsion 
formulation [43].   
3.2.10 In vitro permeation 
In vitro permeation studies using pig ear skin were conducted to mimic human skin. The 
follicular structure of pig ear skin is very similar to humans where their infundibula 
extend deep in the dermis, as in humans [44].  For all formulations, no dutasteride was 
detectable by HPLC in the receptor chamber (LOQ = 3 µg/mL).  Considering, the 
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amount of dutasteride present in the skin (Fig. 9), the highest permeation in the skin 
(12.62 ± 1.72 µg/cm2) was found from the ethanol solution.  
 
This result was in agreement with previous research, in that ethanol acts as a 
penetration enhancer in topical products [45]. There was a significant difference 
(p<0.05) in the amount of dutasteride in the skin from ethanol and the hydrophobic 
drug-nanoparticle formulation. There were significant differences in the amount of 
dutasteride in the skin (p<0.05) when DST-NLCs (6.09 ± 1.09 µg/cm2) were coated 
with 5% CSO-SA (2.82 ± 0.40 µg/cm2), 10% CSO-SA (2.70 ± 0.35 µg/cm2) or CSO 
(2.11 ± 0.64µg/cm2). This result was similar to previous research [46] where they found 
benzophenone-3 loaded chitosan coated polymeric nanocapsules was less in the dermis 
and epidermis compared to uncoated with chitosan. These results could be discussed by 
the different surface charge between polysaccharide from chitosan and the epithelium 
as previously discussed for the ocular epithelium [47] and also the bioadhesive 
characteristic of chitosan [48]. Further experiments such as in vivo studies are required 
to confirm these formulation effects on permeation. In normal application, the same 
concentration of dutasteride will be applied on the scalp where the surface area will be 
much higher. Moreover, massaging of the scalp which will increase the total amount of 
the drug in the skin, since previous research has shown such massage resulted in deeper 
penetration of nanoparticles in the hair follicular region[11]. The small size of these 
DST-NLCs uncoated and coated with CSO-SA (200- 250 nm) will ensure deep 
penetration into the hair follicle duct [11]. The different size of nanoparticles will affect 
the penetration depth [13]. Particles in the size range used in this study would be 
predicted to penetrate the upper part of follicle of terminal hair, and would likely 
penetrate deeper in the vellus hair follicles, especially on the balding site, where the hair 
is short, thin and fine. By contrast, application of ethanol-based formulations produces 
documented adverse reactions. The adverse reactions resulting from ethanol-use as a 
carrier (e.g. scalp dryness, irritation and burning, contact dermatitis [49]), should be 
avoided by using nanoparticle formulations.  
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3.2.11 In vitro cytotoxicity 
After 5 days of treatment with various concentrations of dutasteride (alone) and 
nanoparticles, there was a significant difference (p<0.05) in cytotoxicity values (IC50). 
Dutasteride alone (Fig. 10A) showed cytotoxicity at very low concentrations (IC50 = 
10.4 ± 1.82 µM). Values of IC50 for DST-NLCs, coated and uncoated with CSO-SA 
(Fig. 10B) were higher; up to 59.3 ± 13.1 µM and 58.1 ± 13.0 µM, respectively. For the 
maximum non-toxic concentration (MNTC, EC90), dutasteride without nanoparticles at 
2.1 ± 0.2 µM killed 10% of normal human dermal papilla cells. Meanwhile, dutasteride 
in the nanoparticles either coated with CSO-SA (53.6 ± 8.3 µM) or uncoated (38.1 ± 
13.1 µM) could be applied at a higher concentration compared to the dutasteride without 
nanoparticles. However, NLCs alone (without dutasteride) also showed cytotoxicity 
(IC50 = 58.1 ± 13.0 µM) in a dose-dependent manner. The MNTC (EC90) for NLCs 
uncoated and coated with CSO-SA was 42.3 ± 12.4 µM and 49.4 ± 6.0 µM, respectively. 
There was no significant difference (p<0.05) in MNTC between uncoated DST-NLCs 
and those coated with CSO-SA. This showed that when dutasteride was delivered using 
nanoparticles, it increased MNTC (EC90) of the drug approximately 20-fold, probably 
due to the slow release of the drug from the nanocarrier system. It is interesting to note 
that, NLCs (with no dutasteride) coated and uncoated with CSO-SA also proliferated 
the hair follicle dermal papilla cells at 25 uM (comparable with the formulation 
containing dutasteride) when compared to the control. This shows that, stearic acid acts 
as a main component for the NLCs system and could itself promote hair growth. An 
efficacy study of the formulations on 5α-reductase inhibition is on-going.  
 
4.0 CONCLUSION 
The stearic acid-chitosan conjugate was successfully prepared, as confirmed by 1NMR 
and FTIR analysis. DST-NLCs produced good entrapment efficiency (97.8 ± 0.68%) 
and drug loading (3.49 ± 0.10%), using 17.5 mg of dutasteride in the scaled-up 
formulation. By adding CSO-SA to DST-NLCs, the mean hydrodynamic diameter and 
PDI were increased, and the NLCs had a high positive charge. DST-NLCs coated with 
5% CSO showed good stability after 60 days. The release profile for DST-NLCs coated 
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with CSO-SA indicated slow release over the first 12 h. In the permeation study, no 
dutasteride was detected in the receptor chamber after 48 h, indicating dutasteride has 
low permeability. An amount of 6.09 ± 1.09 µg/cm2 and 2.82 ± 0.40 µg/cm2 respectively, 
of dutasteride were found in the skin after 48 h of the permeation studies, indicating that 
DST-NLCs, uncoated and coated with 5% CSO-SA would be a good carrier for 
dutasteride. By encapsulating the dutasteride in the NLC formulations the maximum 
non-toxic concentration was increased approximately 20-fold. Further work using cell-
uptake studies is required to establish the ability of these, or related formulations to 
target hair follicle dermal papilla cells for promoting the hair growth. As a conclusion, 
dutasteride-loaded nanostructured lipid carriers coated with stearic acid-chitosan 
conjugate (CSO-SA), represent a promising strategy for topical delivery of dutasteride. 
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Table 1 Design of experiment for preparing dutasteride-loaded nanostructured 
lipid carrier (DST-NLCs) using a 23 full factorial design 
Formulation Stearic acid (mg) Lutrol® micro 
68 (mg) 
Phosal® 53 MCT 
(mg) 
S1 50 (-1) 25 (-1) 25 (-1) 
S2 100 (+1) 25 (-1) 25 (-1) 
S3 50 (-1) 50 (+1) 25 (-1) 
S4 100 (+1) 50 (+1) 25 (-1) 
S5 50 (-1) 25 (-1) 50 (+1) 
S6 100 (+1) 25 (-1) 50 (+1) 
S7 50 (-1) 50 (+1) 50 (+1) 
S8 100 (+1) 50 (+1) 50 (+1) 
¥Number in bracket represents the coded value 
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Table 2 Analysis of variance (ANOVA) for 23 full factorial design on hydrodynamic 
diameter (at day 14) 
 Sum of squares df F-value P value 
Model 99861.59 3 26.13 0.0043* 
A 42748.88 1 33.56 0.0044* 
B 7626.12 1 5.99 0.0707 
AB 49486.58 1 38.85 0.0034* 
A – Stearic acid, B – Lutrol® micro 68, C – Phosal® 53 MCT 
* Significance level p<0.05 
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Table 3 Analysis of variance (ANOVA) for 23 factorial design on PDI (day 14) 
 Sum of squares df* F-value P value 
Model 0.046 5 267.18 0.0037* 
A 0.018 1 527.01 0.0019* 
B 1.805 x 10-4 1 5.27 0.1486 
C 0.014 1 412.03 0.0024* 
AB 0.012 1 337.28 0.0030* 
AC 1.861 x 10-3 1 54.32 0.0179* 
A – Stearic acid, B – Lutrol® micro 68, C – Phosal® 53 MCT 
* Significance level p<0.05 
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Table 4 Entrapment efficiency and drug loading of DST-NLCs at day 1 (n=3) 
Formulation  Stearic 
acid (mg) 
Lutrol® 
micro 68 
(mg) 
Phosal® 53 
MCT (mg) 
EE (%) 
(mean ± 
SD) 
DL (%) 
(mean ± 
SD) 
S1 50 25 25 79.6 ± 10.3 4.40 ± 0.58 
S2 100 25 25 81.7 ± 20.3 3.31 ± 0.75 
S3 50 50 25 63.2 ± 21.8 2.98 ± 0.61 
S4 100 50 25 97.6 ± 2.4 3.27 ± 0.07 
S5 50 25 50 80.0 ± 0.6 2.49 ± 0.65 
S6 100 25 50 97.7 ± 1.2 3.09 ± 0.35 
S7 50 50 50 64.8 ± 7.7 2.09 ± 0.32 
S8 100 50 50 92.5 ± 5.6 2.66 ± 0.24 
EE – entrapment efficiency, DL – drug loading 
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Table 5 Analysis of variance (ANOVA) for 23 full factorial design experiment 
variables’ effect on entrapment efficiency 
 Sum of squares df* F-value P value 
Model 1116.71 3 10.46 0.0230* 
A 838.45 1 23.56 0.0083* 
B 54.80 1 1.53 0.2832 
AB 223.66 1 6.28 0.0663 
A – Stearic acid, B – Lutrol ® F68, C – Phosal® 53 MCT, *significance level p<0.05 
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Table 6 Size distribution and surface charge of uncoated DST-NLCs and coated 
with CSOSA or CSO 
Storage condition DST-NLCs DST-NLCs 
5% CSO-SA 
DST-NLCs 
10% CSO-SA 
DST-NLCs 
5% CSO 
Day 1 (Initial)      
Particle size (nm) 187.6 ± 7.0 220.1 ± 11.9 230.1 ± 8.2 208.4 ± 1.6 
PDI 0.117 ± 
0.008 
0.149 ± 
0.024 
0.147 ± 0.026 0.167 ± 0.025 
Zeta potential 
(mV) 
-18 ± 0.9 +26 ± 1.1 +30 ± 1.2 +22 ± 2.1 
Day 30 at 4°C     
Particle size (nm) 216.8 ± 6.0 239.0 ± 24.3 241.9 ± 7.5 Aggregation 
PDI 0.132 ± 
0.017 
0.193 ± 
0.064 
0.213 ± 0.006 Aggregation 
Zeta potential 
(mV) 
-17.2 ± 2.6 33.9 ± 1.8 33.8 ± 1.8 Aggregation 
Day 30 at 25°C     
Particle size (nm) 435.3 ± 32.0 443.6 ± 62.9 Aggregation Aggregation 
PDI 0.208 ± 
0.036 
0.233 ± 
0.032 
Aggregation Aggregation 
Zeta potential 
(mV) 
-17.0 ± 0.7 24.0 ± 1.0 Aggregation Aggregation 
Day 60 at 4°C     
Particle size (nm) 228.5 ± 6.8 243.8.0 ± 
18.8 
259.8 ± 4.2 Aggregation 
PDI 0.128 ± 
0.004 
0.155 ± 
0.025 
0.215 ± 0.020 Aggregation 
Zeta potential 
(mV) 
-17.2 ± 2.6 32.2 ± 10.4 29.4 ± 5.6 Aggregation 
Day 60 at 25°C     
Particle size (nm) 435.3 ± 32.0 578.2 ± 27.0 Aggregation Aggregation 
PDI 0.208 ± 
0.036 
0.274 ± 
0.113 
Aggregation Aggregation 
Zeta potential 
(mV) 
-18.9 ± 1.6 20.0 ± 1.6 Aggregation Aggregation 
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Fig. 1 Conjugation of chitosan oligomer with stearic acid. 
 
 
 
 
 
 
    
37 
 
 
 
 
 
 
Fig. 2 FTIR (a) and 1H NMR (b) spectra of CSO-SA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b)  
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Fig. 3 Hydrodynamic diameter (nm) and particle size distribution for formulations 
of DST-NLCs (day 1 and day 14, n=3 ± s.d.).  
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Fig. 4 3D-surface graph of interaction on hydrodynamic diameter (a) and 
polydispersity index (b and c) at day 14. 
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Fig. 5 Zeta potential of formulations of DST-NLCs at day 1 and day 14 (n=3 ± s.d.).  
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Fig. 6 3D-surface graph of interaction between stearic acid (A) and Lutrol® micro 
68 (B) on entrapment efficiency. 
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Fig. 7 TEM Morphology of DST-NLCs, uncoated (A), coated with; 5% CSO (B), 
5% CSO-SA (C) and 10% CSO-SA (D). 
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Fig. 8 Drug release from different DST-NLCs formulations and control 
(dutasteride in ethanol) (n=3 ± s.d.). 
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Fig. 9 Amount of dutasteride permeated in the skin after 48 hours (n=4 ± s.d.). 
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Fig. 10 Cytotoxicity of dutasteride alone (A), DST-NLCs uncoated and coated with 
CSO-SA and empty NLCs/NLCs-CSOSA (B) on hair follicle dermal papilla cells 
(n=4 ± s.d.).  
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